Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/320300
Type: Artigo de Periódico
Title: Monoclonal Antibody Therapeutics As Potential Interferences On Protein Electrophoresis And Immunofixation
Author: Willrich
MAV; Ladwig
PM; Andreguetto
BD; Barnidge
DR; Murray
DL; Katzmann
JA; Snyder
MR
Abstract: The use of therapeutic recombinant monoclonal antibodies (mAbs) has triggered concerns of misdiagnosis of a plasma cell dyscrasia in treated patients. The purpose of this study is to determine if infliximab (INF), adalimumab (ADA), eculizumab (ECU), vedolizumab (VEDO), and rituximab (RITU) are detected as monoclonal proteins by serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). Methods: Pooled normal sera were spiked with various concentrations (ranging from trough to peak) of INF, ADA, ECU, VEDO and RITU. The peak concentration for VEDO and RITU was also added to samples with known monoclonal gammopathies. All samples were analyzed by SPEP (Helena Laboratories) and IFE (Sebia); sera containing peak concentrations of mAbs were reflexed to electrospray-time-of-flight mass spectrometry (AbSciex Triple TOF 5600) for the intact light chain monoclonal immunoglobulin rapid accurate mass measurement (miRAMM). Results: For all mAbs tested, no quantifiable M-spikes were observed by SPEP at any concentration analyzed. Small. fraction abnormalities were noted on SPEP for VEDO at 300 mu g/mL and RITU at 400 mu g/mL, with identification of small IgG. proteins on IFE. Using miRAMM for peak samples, therapeutic mAbs light chain accurate masses were identified above the polyclonal background and were distinct from endogenous monoclonal gammopathies. Conclusions: MAbs should not be easily confounded with plasma cell dyscrasias in patients undergoing therapy except when a SPEP and IFE are performed within a couple of days from infusion (peak). In ambiguous cases the use of the miRAMM technology could precisely identify the therapeutic mAb distinct from any endogenous monoclonal protein.
Subject: Immunofixation
Monoclonal Antibody Therapies
Monoclonal Immunoglobulin Rapid Accurate Mass Measurement (miramm)
Protein Electrophoresis
Editor: WALTER DE GRUYTER GMBH
Citation: Clinical Chemistry And Laboratory Medicine. WALTER DE GRUYTER GMBH, n. 54, n. 6, p. 1085 - 1093.
Rights: embargo
Identifier DOI: 10.1515/cclm-2015-1023
Address: https://www.degruyter.com/view/j/cclm.2016.54.issue-6/cclm-2015-1023/cclm-2015-1023.xml
Date Issue: 2016
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.